Morgan Stanley upgrades Mphasis stock rating to Overweight on improved growth outlook

Morgan Stanley has upgraded Mphasis Ltd. (NSE:MPHL) to Overweight from Equalweight, significantly raising its price target by 32% to INR3,500.00. This upgrade reflects an improved growth outlook, driven by a resonating go-to-market strategy, an increased qualified deal pipeline, the resolution of the Logistics & Transportation vertical drag, and enhanced conversion of total contract value to revenue. The firm also increased Mphasis's earnings per share estimates for fiscal years 2027 and 2028. Consequently, Morgan Stanley now considers Mphasis its preferred mid-cap play, citing greater upside potential compared to peers.

Analysis

Morgan Stanley has upgraded Mphasis Ltd. (NSE:MPHL) to Overweight from Equalweight, accompanied by a significant 32% price target increase to INR3,500.00 from INR2,650.00. The upgrade is predicated on an improving growth outlook, supported by four key catalysts: a client-resonant go-to-market strategy that is boosting the qualified deal pipeline, the resolution of a previous drag from the Logistics & Transportation vertical, and an accelerating conversion of total contract value into revenue, which points to a stronger quarterly growth cadence. In line with this optimism, the firm has raised its earnings per share estimates for Mphasis by 5.7% for fiscal year 2027 and 5.2% for fiscal year 2028. The new price target is derived from a 30x P/E multiple on June 2027 estimates, reflecting confidence in higher long-term growth and margin assumptions. This move positions Mphasis as Morgan Stanley's preferred mid-cap IT play, with the analysis noting it has more upside potential than peers such as Coforge.

Key Decisions for Investors

• Investors should view this upgrade as a strong positive signal, potentially justifying a re-evaluation of Mphasis for inclusion or an increased weighting in portfolios focused on mid-cap IT services.
• Given that Mphasis is now Morgan Stanley's preferred pick in the sector, investors may consider its relative attractiveness against peers like Coforge, where the perceived upside is now lower.
• The thesis hinges on improved deal-to-revenue conversion and pipeline strength; therefore, monitoring these specific metrics in upcoming quarterly reports is critical to validate the projected growth acceleration.
• Be mindful that the 30x P/E multiple is a premium valuation based on future growth, making the stock sensitive to any potential shortfalls in meeting long-term earnings and margin expectations.